NCT02101775View on ClinicalTrials.gov

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 21, 2014

Primary Completion Date

February 3, 2022

Study Completion Date

February 20, 2026

Conditions
Ovarian Brenner TumorOvarian CarcinosarcomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous CystadenocarcinomaOvarian Serous Surface Papillary AdenocarcinomaOvarian Undifferentiated CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
DRUG

Adavosertib

Given PO

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (16)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

55905

Mayo Clinic in Rochester, Rochester

60637

University of Chicago Comprehensive Cancer Center, Chicago

62526

Decatur Memorial Hospital, Decatur

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

119074

National University Hospital Singapore, Singapore

V1Y 5L3

BCCA-Cancer Centre for the Southern Interior, Kelowna

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital and Cancer Center-General Campus, Ottawa

M5G 2M9

University Health Network Princess Margaret Cancer Center P2C, Toronto

University Health Network-Princess Margaret Hospital, Toronto

H2X 3E4

CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH